JP7583027B2 - プロテアソームのコア粒子の低分子刺激物質 - Google Patents

プロテアソームのコア粒子の低分子刺激物質 Download PDF

Info

Publication number
JP7583027B2
JP7583027B2 JP2022509051A JP2022509051A JP7583027B2 JP 7583027 B2 JP7583027 B2 JP 7583027B2 JP 2022509051 A JP2022509051 A JP 2022509051A JP 2022509051 A JP2022509051 A JP 2022509051A JP 7583027 B2 JP7583027 B2 JP 7583027B2
Authority
JP
Japan
Prior art keywords
substituted
heteroaralkyl
aralkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544536A5 (enExample
JP2022544536A (ja
Inventor
ダーシー ジェイ． トレイダー，
レイチェル アン コールマン，
アンドレス サラザール－チャパーロ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2022544536A publication Critical patent/JP2022544536A/ja
Publication of JP2022544536A5 publication Critical patent/JP2022544536A5/ja
Application granted granted Critical
Publication of JP7583027B2 publication Critical patent/JP7583027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022509051A 2019-08-16 2020-08-14 プロテアソームのコア粒子の低分子刺激物質 Active JP7583027B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962887732P 2019-08-16 2019-08-16
US62/887,732 2019-08-16
PCT/US2020/046269 WO2021034627A1 (en) 2019-08-16 2020-08-14 Small molecule stimulators of the core particle of the proteasome

Publications (3)

Publication Number Publication Date
JP2022544536A JP2022544536A (ja) 2022-10-19
JP2022544536A5 JP2022544536A5 (enExample) 2023-06-15
JP7583027B2 true JP7583027B2 (ja) 2024-11-13

Family

ID=74659522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022509051A Active JP7583027B2 (ja) 2019-08-16 2020-08-14 プロテアソームのコア粒子の低分子刺激物質

Country Status (5)

Country Link
US (1) US20220267280A1 (enExample)
EP (1) EP4013405A4 (enExample)
JP (1) JP7583027B2 (enExample)
CN (1) CN114222573A (enExample)
WO (1) WO2021034627A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113620881A (zh) * 2021-08-12 2021-11-09 浙江禾本科技股份有限公司 一种1-[2-(2,4-二氯苯基)-2羟基乙基]-1h咪唑的合成方法
WO2023036936A1 (en) 2021-09-09 2023-03-16 Booster Therapeutics Gmbh Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
EP4147723A1 (en) 2021-09-09 2023-03-15 Booster Therapeutics GmbH Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
WO2025219559A1 (en) 2024-04-18 2025-10-23 Booster Therapeutics Gmbh Pyrrolidine compounds as proteasome stimulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503111A (ja) 2009-08-28 2013-01-31 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． アラルキルベンジルエーテル化合物、その製造方法、中間体化合物、そのような化合物の使用、治療および／または予防の方法、それを含む薬学的組成物および医薬
JP2018521133A (ja) 2015-07-16 2018-08-02 アマリ バイオファーマ， インコーポレイテッド プラチナ薬剤の毒性の予防方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
US3991202A (en) * 1974-01-31 1976-11-09 Janssen Pharmaceutica N.V. Imidazolium salts
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
NZ328607A (en) * 1996-09-09 1999-08-30 Hoffmann La Roche Heterocyclically substituted n-benzyl-azolium derivatives and fungicidal compositions
EP0829478A3 (en) * 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
WO2004022546A1 (ja) * 2002-09-04 2004-03-18 Keimei Oh ジャスモン酸の生合成を阻害する物質
EP1896406A2 (en) * 2005-06-14 2008-03-12 Shering Corporation The preparation and use of compounds as protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503111A (ja) 2009-08-28 2013-01-31 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． アラルキルベンジルエーテル化合物、その製造方法、中間体化合物、そのような化合物の使用、治療および／または予防の方法、それを含む薬学的組成物および医薬
JP2018521133A (ja) 2015-07-16 2018-08-02 アマリ バイオファーマ， インコーポレイテッド プラチナ薬剤の毒性の予防方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACS Chemical Biology ，2014年，9 (2)，Pages 433-442
Biochemical Pharmacology ，2000年，60 (3)，Pages 317-324
Bioorganic & Medicinal Chemistry ，2018年，26 (8)，Pages 1665-1674
Journal of Enzyme Inhibition and Medicinal Chemistry，2006年，21 (3)，Pages 293-303
PLOS One ，2007年，2 (6)，e545
PubChem [online]，2005.08.01 [検索日 2024.04.18] PubChem CID 487082
PubChem [online]，2017.01.25 [検索日 2024.04.18] PubChem CID 123578921
Toxicology and Applied Pharmacology，2002年，180 (1)，Pages 22-35

Also Published As

Publication number Publication date
EP4013405A1 (en) 2022-06-22
WO2021034627A1 (en) 2021-02-25
US20220267280A1 (en) 2022-08-25
CN114222573A (zh) 2022-03-22
JP2022544536A (ja) 2022-10-19
EP4013405A4 (en) 2023-08-09

Similar Documents

Publication Publication Date Title
US20250000863A1 (en) Combination therapies of kras g12d inhibitors with sos1 inhibitors
US20260085058A1 (en) Degraders of son of sevenless homolog 1
EP3849534B1 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
US10905665B2 (en) Chemical modulators of signaling pathways and therapeutic use
JP2022544536A (ja) プロテアソームのコア粒子の低分子刺激物質
Byun et al. Design, synthesis, and biological activity of marinacarboline analogues as STAT3 pathway inhibitors for docetaxel-resistant triple-negative breast cancer
RS66424B1 (sr) Kombinovane terapije
CA2843417A1 (en) Treatment of breast cancer
CN108101890A (zh) N-磺酰基吡咯衍生物
US20250127908A1 (en) Heterobifunctional conditional inhibitors
WO2022035898A1 (en) Proteasome enhancers and uses thereof
US11987579B2 (en) Niclosamide analogues and therapeutic use thereof
WO2020247537A1 (en) Compounds that degrade kinases and uses thereof
US9403800B2 (en) Compounds for inhibition of cancer cell proliferation
US10494365B2 (en) Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereof
CA3231240A1 (en) Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors
US11028096B2 (en) Tricyclic P2-ligand containing potent HIV-protease inhibitors against HIV/AIDS
US12060337B2 (en) Substituted dibenzo[b, f]azepines as proteasome activators
US11807631B2 (en) Herboxidiene derivatives and uses thereof
US10981875B2 (en) Quinolone-based compounds with anticancer activity
WO2025017207A1 (en) Inhibitors of smndc1 and their therapeutic use
US11439656B2 (en) Pharmaceutical compounds and uses thereof
WO2023147485A2 (en) Proteasome enhancers and uses thereof
WO2025049624A1 (en) Prodrugs of nicotinamide n-methyltransferase (nnmt) inhibitors and uses thereof
CA3191312A1 (en) Proteasome enhancers and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241031

R150 Certificate of patent or registration of utility model

Ref document number: 7583027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150